CD86 and malignant colon neoplasm: Seven checkpoint-related genes (BTLA,CD80, CD86, CTLA4, IDO1, PDCD1LG2, and TIGIT) had decreased expression in the KRAS-mutated group, providing potential opportunities for immunotherapy in colon cancer.